Tonix Pharmaceuticals: FDA AdCom News Positive, But Making Bull Case Is Problematic
Tonix Pharma (TNXP) has submitted an NDA for its candidate TNX-102 SL for fibromyalgia, with a PDUFA date set for August 15, 2025. See why I'm on the sidelines.
Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025
The data to be presented encompasses five of the company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 ...
Le Lézard13h
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, announced today multiple oral and poster presentations at the ...
Nitish criticises RJD lawmakers for wearing t-shirts in assembly
Patna: With the state assembly elections just a few months away, the opposition Rashtriya Janata Dal (RJD) is once again ...
Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years
FDA reviews TNX-102 SL for Fibromyalgia by August 2025, with no advisory required. See why we recommend a buy on TNXP stock.
National Law Review16h
Breaking Down the New No Surprises Act FAQs Post-TMA III
The new FAQs essentially preserve the existing circumstances, as the enforcement discretion has been operative since fall ...
JD Supra15h
A Recent Tax Ruling Has Made ANDA Litigation Less Burdensome for Generics
In Actavis v. U.S., a case at the intersection of tax law and patent law, the Federal Circuit held that generic drug companies’ ...
NDTV12h
India News
Comedian Samay Raina has been summoned by the Maharashtra Cyber Cell to appear for case proceedings of the 'India's Got Latent' controversy.